BKTH.US Breakthrough Chemistry, Inc.
- Market cap
- USD 725K
- P/E
- -
- P/B
- -
- ROE
- -517.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BKTH.US undervalued?
Graham numberThe Graham number of Breakthrough Chemistry, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Breakthrough Chemistry, Inc. fundamental analysis
No fundamental analysis for Breakthrough Chemistry, Inc. yet.
Breakthrough Chemistry, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Breakthrough Chemistry, Inc.
Breakthrough Chemistry, Inc. develops compounds and formulations that defy the norms prevalent in chemical industries. The company's chemistry platform offers solutions for food security and spoilage reduction, natural resource conservation, personal hygiene, protective coatings, odor elimination, and chemical neutralization. Breakthrough Chemistry, Inc. was formerly known as Megola, Inc. and changed its name to Breakthrough Chemistry, Inc. in July 2025. The company is based…
Full company profileBreakthrough Chemistry, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Breakthrough Chemistry, Inc. annual financial statements
| Item | 2013 | 2014 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 95.6K | 16.7K | 13.8K | 18.9K | 33.8K | 15.1K | 10.0K |
| Gross Profit | - | - | - | - | 28.5K | 7.34K | -14.9K | -43.8K | -24.1K | -25.3K | - |
| Operating Income | -430K | -30.1K | -30.0K | -25.1K | -44.5K | -69.5K | -135K | -185K | -85.5K | -145K | -120K |
| EBITDA | -430K | -30.1K | -30.0K | -25.1K | -44.5K | -69.5K | -110K | -141K | -40.7K | -107K | -120K |
| Net Income | -430K | -30.1K | -46.6M | 28.1M | 18.2M | -151K | -187K | -221K | -46.7K | 1.44M | -4.33M |
| EPS | -0.22 | -0.01 | -7.12 | 0.07 | 2.39 | -0.02 | -0.02 | -0.02 | 0.00 | 0.00 | -0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 2.50M | - | - | - | 69.3K | 81.5K | 1.05M | 953K | 859K | 2.33M | 1.30M |
| Total Liabilities | 205K | - | - | - | 143K | 286K | 361K | 433K | 386K | 413K | 463K |
| Shareholders' Equity | 2.30M | - | - | - | -73.5K | -204K | 685K | 520K | 473K | 1.92M | 837K |
| Cash & Short-term Investments | 1.16K | - | - | - | - | 15.8K | 850.00 | 957.00 | 652.00 | 1.91M | 1.22M |
| Total Debt | - | - | - | - | 64.9K | 221K | 245K | 222K | 191K | 195K | 195K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | - | - | - | -76.6K | -90.7K | -98.9K | -58.8K | -13.1K | - |
| Capital Expenditure | - | - | - | - | - | 0.00 | 0.00 | 3.00 | 3.00 | 3.00 | - |
| Free Cash Flow | - | - | - | - | - | -76.6K | -90.7K | -98.9K | -58.8K | -13.1K | - |
| Ratios | |||||||||||
| ROE | -18.7% | - | - | - | - | - | -27.3% | -42.5% | -9.9% | 75.1% | -517.3% |
| ROA | -17.2% | - | - | - | 26,180.4% | -185.9% | -17.9% | -23.2% | -5.4% | 61.8% | -333.1% |
| Net Profit Margin | - | - | - | - | 18,996.1% | -905.8% | -1,354.0% | -1,166.5% | -138.4% | 9,569.5% | -43,312.4% |
| Debt to Equity | - | - | - | - | - | - | 0.36x | 0.43x | 0.40x | 0.10x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Breakthrough Chemistry, Inc. dividends
Breakthrough Chemistry, Inc. has not paid dividends in the last 10 fiscal years.
Last stock split: 1:30 on Jul 29, 2025.
Who owns Breakthrough Chemistry, Inc.
Ownership data of Breakthrough Chemistry, Inc. is not available yet.
Breakthrough Chemistry, Inc. company profile
- Company name
- Breakthrough Chemistry, Inc.
- Ticker
- BKTH.US
- Exchange
- USA Stocks
- Sector
- Industrials
- Industry
- Pollution & Treatment Controls
- Fiscal year end
- March
- Address
- 8891 Brighton Lane, Bonita Springs, FL, United States, 34135
- Phone
- 888 587 1698
- Website
- megolacorp.com
About Breakthrough Chemistry, Inc.
Breakthrough Chemistry, Inc. develops compounds and formulations that defy the norms prevalent in chemical industries. The company's chemistry platform offers solutions for food security and spoilage reduction, natural resource conservation, personal hygiene, protective coatings, odor elimination, and chemical neutralization. Breakthrough Chemistry, Inc. was formerly known as Megola, Inc. and changed its name to Breakthrough Chemistry, Inc. in July 2025. The company is based in Bonita Springs, Florida.
Breakthrough Chemistry, Inc. management
2- Mr. Robert GardinerPresident, CEO & Director
- Mr. Mark F. SuchyCFO & Director